I'm LongbridgeAI, I can summarize articles.Merck presented first Phase 3 INTerpath-001 data on intismeran plus Keytruda for resected melanoma at ESMO 2026. The company highlighted three late-breaking symposia covering melanoma and endometrial cancer studies, including sacituzumab tirumotecan and Keytruda monotherapy in dMMR endometrial cancer. These disclosures aim to drive future label expansions and pipeline value.
- Merck flagged first-time pivotal Phase 3 data from its oncology pipeline for presentation at ESMO 2026 in Madrid. * Results have not been presented yet; three late-breaking Presidential Symposia will feature melanoma and endometrial cancer studies. * Key readouts cover intismeran autogene with Keytruda in resected melanoma, sacituzumab tirumotecan in post-treatment endometrial cancer. * A separate Phase 3 trial will present Keytruda monotherapy as an initial treatment option in dMMR advanced or recurrent endometrial cancer. * Merck positioned the set of Phase 3 disclosures as a potential driver of future label expansion and pipeline value in oncology. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261013301331) on October 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)